PRAC wants fusafungine off the market

16 February 2016 - Deborah Wilkes

Archived

Concerns about serious allergic reactions have led the European Union's Pharmacovigilance Risk Assessment Committee (PRAC) to recommend that nasal and mouth sprays containing the antibiotic fusafungine should be taken off the market. The medicines – which are used to treat upper airway infections including colds – have non-prescription status in a number of countries, including Germany, Hungary, Portugal and Spain.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: